Molecular pathogenesis and molecular therapy in RUNX1-EVI1-type leukemia.

RUNX1-EVI1型白血病的分子发病机制和分子治疗。

• 批准号: 19K08822
• 负责人: Mitani Kinuko
• 金额: $ 2.83万
• 依托单位: Dokkyo Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2019
• 资助国家: 日本
• 起止时间: 2019-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-19K08822/
• 关键词: RUNX1-EVI1; t(3;21); 急性巨核芽球性白血病; SKP2; ヒストン脱アセチル化酵素阻害剤; 内科; 癌; 遺伝子; 分子標的療法

项目成果

Clonal hematopoiesis in adult pure red cell aplasia

成人纯红细胞再生障碍性克隆造血

• DOI: 10.1038/s41598-021-81890-5
• 发表时间: 2021
• 影响因子: 4.6
• 作者: Fujishima N;Kohmaru J;Koyota S;Kuba K;Saga T;Omokawa A;Moritoki Y;Ueki S;Ishida F;Nakao S;Matsuda A;Ohta A;Tohyama K;Yamasaki H;Usuki K;Nakashima Y;Sato S;Miyazaki Y;Nannya Y;Ogawa S;Sawada K;Mitani K;Hirokawa M
• 通讯作者: Hirokawa M

ASXL1 mutations predict a poor response to darbepoetin alfa in anemic patients with low-risk MDS.

ASXL1 突变预示低危 MDS 贫血患者对达贝泊汀阿尔法反应不佳。

• 发表时间: 2020
• 作者: Hirohiko Shibayama; Yasuyoshi Morita; Motoshi Ichikawa; Yasuhito Nannya; Hitoshi Hanamoto; Yoshinobu Maeda; Tomoko Hata; Toshihiro Miyamoto; Hiroshi Kawabata; Kazuto Takeuchi; Hiroko Tanaka; Junji Kishimoto; Satoru Miyano; Itaru Matsumura; Seishi Ogawa; K
• 通讯作者: K

Clonal evolution and clinical impact of genetic lesions in blast crisis of chronic myeloid leukemia.

慢性粒细胞白血病急变中遗传病变的克隆进化和临床影响。

• 发表时间: 2021
• 作者: 越智 陽太郎;吉田 健一;南谷 泰仁;佐々木 光;三谷 絹子;小川 誠司等
• 通讯作者: 小川 誠司等

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.

慢性粒细胞白血病母细胞转化中遗传异常的克隆进化和临床意义。

• DOI: 10.1038/s41467-021-23097-w
• 发表时间: 2021-05-14
• 作者: Ochi Y;Yoshida K;Huang YJ;Kuo MC;Nannya Y;Sasaki K;Mitani K;Hosoya N;Hiramoto N;Ishikawa T;Branford S;Shanmuganathan N;Ohyashiki K;Takahashi N;Takaku T;Tsuchiya S;Kanemura N;Nakamura N;Ueda Y;Yoshihara S;Bera R;Shiozawa Y;Zhao L;Takeda J;Watatani Y;Okuda R;Makishima H;Shiraishi Y;Chiba K;Tanaka H;Sanada M;Takaori-Kondo A;Miyano S;Ogawa S;Shih LY
• 通讯作者: Shih LY

Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.

一名慢性粒细胞白血病患者出现 IDH2 和 NPM1 突变的费城染色体阴性急性粒细胞白血病，该患者对酪氨酸激酶抑制剂治疗表现出主要的分子反应。

• DOI: 10.1007/s12185-020-03074-7
• 发表时间: 2021
• 影响因子: 2.1
• 作者: Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; H;a T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K.
• 通讯作者: Mitani K.